Trastuzumab Clinical Trials
67 recruitingDrug
Phase 239Phase 316Phase 115Phase 45
Showing 1–20 of 67 trials
Recruiting
Phase 3
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
Gastroesophageal Junction AdenocarcinomaHER2-positive Gastric Cancer
AstraZeneca840 enrolled286 locationsNCT06764875
Recruiting
Phase 1
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Fate Therapeutics113 enrolled5 locationsNCT07216105
Recruiting
Phase 3
A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer
Resectable HER2-positive Breast Cancer
Shanghai JMT-Bio Inc.1,800 enrolled1 locationNCT07441460
Recruiting
Phase 2
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
Metastatic Salivary Gland CarcinomaStage III Major Salivary Gland Cancer AJCC v8Stage IV Major Salivary Gland Cancer AJCC v8+2 more
NRG Oncology146 enrolled150 locationsNCT05408845
Recruiting
Phase 2
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
Breast CancerER Positive Breast CancerHER2-positive Breast Cancer+1 more
Ruth O'Regan30 enrolled4 locationsNCT04886531
Recruiting
Phase 1Phase 2
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Metastatic Breast CancerEsophageal AdenocarcinomaGastroesophageal Junction Adenocarcinoma+1 more
Boehringer Ingelheim768 enrolled107 locationsNCT06324357
Recruiting
Phase 1
A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants
Healthy Participants
Genentech, Inc.312 enrolled4 locationsNCT07214766
Recruiting
Phase 2
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
ALX Oncology Inc.120 enrolled28 locationsNCT07007559
Recruiting
Phase 1
Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer
HER2-positive Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute28 enrolled1 locationNCT05378464
Recruiting
Phase 1Phase 2
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
Advanced Solid Tumor
DualityBio Inc.1,000 enrolled24 locationsNCT05785741
Recruiting
Phase 2
Tucatinib+Trastuzumab+Eribulin in HER2+ MBC
Breast CancerPretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer
Criterium, Inc.30 enrolled6 locationsNCT05458674
Recruiting
Phase 1
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Metastatic Breast CancerAdvanced Breast CancerMetastatic Lung Cancer+6 more
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)392 enrolled34 locationsNCT06625775
Recruiting
Phase 4
Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie
OncologyInfusion Reaction
Isala776 enrolled1 locationNCT06031233
Recruiting
Phase 1
CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
Esophageal CancerGastric CancerEsophagus Cancer+1 more
Washington University School of Medicine42 enrolled1 locationNCT05187182
Recruiting
Phase 3
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
Gastric Cancer
Daiichi Sankyo726 enrolled250 locationsNCT06731478
Recruiting
Phase 2
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
Breast CancerHER2-positive Breast Cancer
Jazz Pharmaceuticals125 enrolled21 locationsNCT07102381
Recruiting
Phase 1
Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)
Gastroesophageal Adenocarcinoma
University of California, Irvine20 enrolled1 locationNCT05733689
Recruiting
Phase 2
A Study of Tucatinib and Trastuzumab in People With Rectal Cancer
Rectal CancerRectal AdenocarcinomaAdenocarcinoma of the Rectum+2 more
Memorial Sloan Kettering Cancer Center37 enrolled7 locationsNCT05672524
Recruiting
Phase 2
Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab
HER2-positive Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute53 enrolled1 locationNCT05325632
Recruiting
Phase 3
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
Gastric CancerGastroesophageal-junction CancerHER2-positive Gastric Cancer+1 more
Shanghai Henlius Biotech550 enrolled208 locationsNCT06532006